156
Views
0
CrossRef citations to date
0
Altmetric
Perspective

Considering Tapentadol As A First-Line Analgesic: 14 Questions

, , , , &
Pages 331-339 | Received 19 Dec 2016, Accepted 04 Apr 2017, Published online: 24 Apr 2017
 

Abstract

Tapentadol is the newest centrally acting analgesic to be approved by the US FDA and regulatory bodies in other countries. It has been called the first-in-class of a novel-acting analgesic mechanism of action that combines µ-opioid receptor agonist activity with neuronal norepinephrine-reuptake inhibition in a single molecule. This duality of action should combine inhibition of ascending (afferent) pain-transmitting signals with activation of descending (efferent) pain-attenuating systems (e.g., diffuse noxious inhibitory controls). However, not all novel mechanisms of action impart the characteristics needed for an analgesic to be considered for first-line therapy. These key questions may help inform clinical decision making.

Financial & competing interests disclosure

JV Pergolizzi is a speaker for Janssen, Grunenthal, Purdue Pharma, Mundipharma, Insys Therapeutics and Johnson & Johnson; he is a researcher for Purdue Pharma, Covidien and Insys Therapeutics; he is a consultant for Grunenthal, Janssen, Purdue Pharma, Covidien, Merck and Johnson & Johnson. He is co-founder of NEMA Research, Inc., a clinical research organization which provides clinical, regulatory and product development services to a number of pharmaceutical companies. F Breve is an independent consultant, received no financial consideration, and has nothing to disclose. R Taylor is executive director of operations at NEMA Research, Inc. RB Raffa is a speaker, consultant and/or basic science investigator for several pharmaceutical companies involved in analgesics research but receives no royalty (cash or otherwise) from sale of any product. SE Strasburger is a student, received no financial consideration, and has nothing to disclose. JA LeQuang is Director of Scientific Communications at NEMA Research, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.